Visual Acuity Outcome Differences Between the Alcon Vivity Toric IOL and RxSight LAL+

Starting soon · Not applicable

Conditions studied: Cataract

In brief

Phase 1 will be ambispective, multi-site, single arm study in age-related cataract patients with regular astigmatism, who were bilaterally treated with the LAL+ IOLs Phase 2 will be a prospective, randomized, unmasked, comparative, multi-site study with 90 days of follow up. Subjects will be randomized in a 1:1 manner to LAL+ or Clareon VIvity Toric IOLs.

Key facts

Study ID
NCT06574646
Run by
The Eye Associates
People needed
250
Starts
2024-10-15
Expected to finish
2026-08-01
Last updated by the study team
2024-08-28

Who can join

Age: 45 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.